Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.

doi:10.1016/j.ejca.2020.07.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2020

Stahler Arndt, Stintzing Sebastian, von Einem Jobst C, Westphalen Christoph B, Heinrich Kathrin, Krämer Nicole, Michl Marlies, Modest Dominik P, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Moehler Markus, Kaiser Florian, Kirchner Thomas, Jung Andreas, Heinemann Volker

Abstract excerpt

BACKGROUND: Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable precision oncology. MATERIAL AND METHODS: FoundationOne® next-generation sequencing identified single-nucleotide variants (SNVs), copy number alterations, high TMB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Cancer Treatments and Studies

Share to Colorectal Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Microsatellite Instability

Share to Neoplasm Metastasis

Share to Polymorphism, Single Nucleotide

Share to Tumor Burden

Source

Open in PubMed

Identifiers

PMID: 32810748
DOI: 10.1016/j.ejca.2020.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.PMID 32810748Read ↗

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.Semantic proximity Read ↗

Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.Semantic proximity Read ↗

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.Semantic proximity Read ↗

Next-Generation Sequencing in Colorectal Cancer: Real-World Molecular Profiling and Clinical Correlations.Semantic proximity Read ↗

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal CancerSemantic proximity Read ↗

Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910.Semantic proximity Read ↗

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.Semantic proximity Read ↗

Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and OxaliplatinSemantic proximity Read ↗

Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Clinical-grade whole genome sequencing of colorectal cancer and 3’ transcriptome analysis demonstrate targetable alterations in the majority of patientsSemantic proximity Read ↗

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.